M Kassiou

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi request reprint Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter
    Yolanda Zea-Ponce
    Faculte de Pharmacie, INSERM U619, Laboratoire de Biophysique Medicale, 31 Av Monge, 37200 Tours, France
    Bioorg Med Chem 13:745-53. 2005
  2. ncbi request reprint Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Appl Radiat Isot 57:713-7. 2002
  3. ncbi request reprint Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    Bioorg Med Chem 13:3623-6. 2005
  4. ncbi request reprint Ligands for peripheral benzodiazepine binding sites in glial cells
    Michael Kassiou
    Ramaciotti Centre for Brain Imaging, Brain and Mind Research Institute BMRI, University of Sydney, NSW, Australia
    Brain Res Brain Res Rev 48:207-10. 2005
  5. ncbi request reprint Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown NSW 2050 Australia
    Synapse 45:95-104. 2002
  6. ncbi request reprint (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, NSW 2050, Camperdown, Australia
    Nucl Med Biol 29:295-302. 2002
  7. ncbi request reprint In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    Nucl Med Biol 28:165-75. 2001
  8. ncbi request reprint Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Life Sci 69:669-75. 2001
  9. doi request reprint Attenuation correction for the large non-human primate brain imaging using microPET
    S Naidoo-Variawa
    Discipline of Medical Radiation Sciences, Faculty of Health Sciences, University of Sydney, PO Box 170, Lidcombe, NSW 1825, Sydney, Australia
    Phys Med Biol 55:2351-63. 2010
  10. ncbi request reprint The influence of tomograph sensitivity on kinetic parameter estimation in positron emission tomography imaging studies of the rat brain
    S R Meikle
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia
    Nucl Med Biol 27:617-25. 2000

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter
    Yolanda Zea-Ponce
    Faculte de Pharmacie, INSERM U619, Laboratoire de Biophysique Medicale, 31 Av Monge, 37200 Tours, France
    Bioorg Med Chem 13:745-53. 2005
    ..4 nM) and (E)-(S,S)-5-AOIBV (Kd=4.3 nM). (R,R)-3, and (R,R)-4 showed the same high affinity for VAChT as (-)-5-IBVM and may be suitable as imaging agents of cholinergic nerve terminals...
  2. ncbi request reprint Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Appl Radiat Isot 57:713-7. 2002
    ..The tracer purified by RP-HPLC was obtained in 70% radiochemical yield with a specific radioactivity of 20 GBq/micromol. Radiochemical and chemical purities measured by radio-TLC and HPLC were >98%...
  3. ncbi request reprint Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    Bioorg Med Chem 13:3623-6. 2005
    ..The evaluation of this radioligand in vivo in the mouse clearly indicates that it does not possess the required properties for studying sigma-2 receptors in the brain using PET...
  4. ncbi request reprint Ligands for peripheral benzodiazepine binding sites in glial cells
    Michael Kassiou
    Ramaciotti Centre for Brain Imaging, Brain and Mind Research Institute BMRI, University of Sydney, NSW, Australia
    Brain Res Brain Res Rev 48:207-10. 2005
    ....
  5. ncbi request reprint Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown NSW 2050 Australia
    Synapse 45:95-104. 2002
    ..These preliminary results suggest that [(76)Br]BrPH has the potential to be a useful radioligand for studying the pharmacology of nicotinic acetylcholine receptors in preclinical experiments...
  6. ncbi request reprint (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET
    Michael Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, NSW 2050, Camperdown, Australia
    Nucl Med Biol 29:295-302. 2002
    ..These results suggest that (+)-[76Br]A-69024 may deserve further investigation as a potential radioligand for studying striatal and cortical dopamine D1 receptors using PET...
  7. ncbi request reprint In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    Nucl Med Biol 28:165-75. 2001
    ..In this preliminary study, we have demonstrated for the first time in vivo upregulation of neuronal nAChR binding following chronic (-)-nicotine treatment...
  8. ncbi request reprint Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors
    M Kassiou
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Life Sci 69:669-75. 2001
    ..2-[123I]A-69024 displays enantioselectivity for dopamine D1 receptors and may deserve further investigation as a possible SPECT radioligand...
  9. doi request reprint Attenuation correction for the large non-human primate brain imaging using microPET
    S Naidoo-Variawa
    Discipline of Medical Radiation Sciences, Faculty of Health Sciences, University of Sydney, PO Box 170, Lidcombe, NSW 1825, Sydney, Australia
    Phys Med Biol 55:2351-63. 2010
    ....
  10. ncbi request reprint The influence of tomograph sensitivity on kinetic parameter estimation in positron emission tomography imaging studies of the rat brain
    S R Meikle
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia
    Nucl Med Biol 27:617-25. 2000
    ..We conclude that effective tomograph sensitivity of 3% may be an appropriate design goal for rat brain imaging...
  11. doi request reprint Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands
    Iman A Moussa
    School of Chemistry, Discipline of Medical Radiation Sciences, University of Sydney, Sydney, NSW, Australia
    J Med Chem 53:6228-39. 2010
    ..The in vivo evaluation of [11C]13 indicates that this radiotracer is a suitable candidate for imaging the sigma1 receptor in neurodegenerative processes...
  12. ncbi request reprint 3-Pyridyl ethers as SPECT radioligands for imaging nicotinic acetylcholine receptors
    D J Henderson
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Sydney 2050, Australia
    Appl Radiat Isot 60:669-76. 2004
    ..3 nM, compared to the 5-bromo and 5-iodo compounds, 5 Ki =3.3 nM and 3 Ki =40.8 nM, respectively. Taken together, these results clearly indicate that 5-[123I]iodo-A-84543 is not suitable for the study of nAChRs in vivo using SPECT...
  13. ncbi request reprint In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the sigma 1 binding sites
    V H Nguyen
    Department of Pharmacology, The University of Sydney, NSW, Australia
    Nucl Med Biol 26:209-15. 1999
    ..Therefore, [3H]ANSTO-14 is a suitable ligand for labelling sigma 1 sites in vitro but is not suitable for brain imaging of sigma binding sites in vivo...
  14. doi request reprint Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model
    S T Warraich
    Department of Pharmacology, Bosch Institute and School of Medical Sciences, University of Sydney, NSW 2006, Australia
    Brain Res Bull 78:85-90. 2009
    ..However levodopa-treated rats were slower than either controls or BZAD-01-treated rats in the locomotor test. The improvement in the apomorphine rotation test suggests that BZAD-01 may be a useful adjunct to levodopa monotherapy...
  15. ncbi request reprint Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions
    L Truong
    Department of Pharmacology, Institute for Biochemical Research, Bosch Building, School of Medical Sciences, University of Sydney, NSW 2006, Australia
    Behav Brain Res 169:1-9. 2006
    ..This graded model can be useful for testing potential neuroprotective compounds for PD...
  16. doi request reprint Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions
    L Truong
    Department of Pharmacology, Bosch Building, Bosch Institute and School of Medical Sciences, University of Sydney, NSW 2006, Australia
    Brain Res Bull 78:91-6. 2009
    ..The latter was also improved by l-dopa in this model. These data support the use of selective NR1/NR2B NMDA antagonists in the therapeutics of PD...
  17. ncbi request reprint Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists
    C Beinat
    School of Chemistry, University of Sydney, NSW 2006, Australia
    Curr Med Chem 17:4166-90. 2010
    ..This review describes recent advances in the development of NR2B antagonists as well as their therapeutic applications...
  18. doi request reprint Challenges in molecular imaging of Parkinson's disease: a brief overview
    Michael Kassiou
    Discipline of Medical Radiation Sciences, University of Sydney, NSW 2006, Australia
    Brain Res Bull 78:105-8. 2009
    ..This brief overview aims to outline the challenges and capabilities of PET and the more commonly used molecular probes in PD studies...
  19. ncbi request reprint Decreased vesicular acetylcholine transporter and alpha(4)beta(2) nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning
    Mitchell Quinlivan
    Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 Avenue Monge, 37200 Tours, France
    Neurosci Lett 415:97-101. 2007
    ..The results with (125)I-A-85380 are unique and are in contrast with work performed in this animal model with other nAChR radioligands, indicating the favourable properties of this radioligand for molecular imaging...
  20. ncbi request reprint Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG PET imaging)
    Armin Mohamed
    Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia
    Eur J Nucl Med Mol Imaging 32:180-5. 2005
    ....
  21. ncbi request reprint High-resolution imaging of the large non-human primate brain using microPET: a feasibility study
    S Naidoo-Variawa
    Discipline of Medical Radiation Sciences, Faculty of Health Sciences, University of Sydney, PO Box 170, Lidcombe, NSW 1825, Sydney, Australia
    Phys Med Biol 52:6627-38. 2007
    ..Further work to develop suitable correction algorithms for high-resolution large primate imaging is warranted...
  22. pmc The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats
    C Hicks
    School of Psychology, Brennan MacCallum Building, University of Sydney, Sydney, Australia
    J Neuroendocrinol 24:1012-29. 2012
    ..Antagonism of the V(1a) R by WAY 267,464 could underlie some of the prosocial effects of this drug either through a direct action or through disinhibition of oxytocin circuitry that is subject to vasopressin inhibitory influences...
  23. ncbi request reprint Development of ligands for the peripheral benzodiazepine receptor
    Michelle L James
    Department of Pharmacology, University of Sydney, NSW 2006, Australia
    Curr Med Chem 13:1991-2001. 2006
    ..This review highlights the main classes of PBR ligands to date. In addition the biological activity and therapeutic potential of certain PBR ligands is discussed...
  24. doi request reprint Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease
    K R Leaver
    Department of Pharmacology, Bosch Institute and School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia
    Clin Exp Pharmacol Physiol 35:1388-94. 2008
    ..Furthermore, there was no significant difference in any of the behavioural measures between lesioned rats pretreated with BZAD-01 and rats that underwent sham surgery...
  25. doi request reprint DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization
    Michelle L James
    Department of Pharmacology, University of Sydney, Sydney, New South Wales, Australia
    J Nucl Med 49:814-22. 2008
    ..Radioligands for the TSPO can therefore measure active disease in the brain. This article details the synthesis, radiofluorination, and pharmacologic evaluation of a new TSPO-specific pyrazolopyrimidine, DPA-714...
  26. doi request reprint Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions
    Addy van Dijk
    Department of Pharmacology, Institute for Biomedical Research, School of Medical Sciences, Bosch Building, University of Sydney, NSW 2006, Australia
    Behav Brain Res 190:14-21. 2008
    ..vehicle treated rats so no neuroprotective effect was demonstrated in this model at the doses utilised...
  27. doi request reprint Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling
    Samuel D Banister
    School of Chemistry, University of Sydney, NSW 2006, Australia
    Bioorg Med Chem Lett 20:145-8. 2010
    ..Molecular modeling was undertaken to rationalize these results...
  28. ncbi request reprint Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects
    Xiang Liu
    Department of Pharmacology, University of Sydney, NSW 2006, Australia
    Eur J Pharmacol 555:37-42. 2007
    ..The differential effect of TC1 and TC4 warrants further study of the mechanism of these actions. Present data also suggests a potential role for trishomocubane analogues in developing medication or research tools for cocaine addiction...
  29. doi request reprint Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening
    Hendra Gunosewoyo
    School of Chemistry, University of Sydney, NSW 2006, Australia
    Bioorg Med Chem 17:4861-5. 2009
    ..This perspective will attempt to highlight some of the most recent key findings in both the biology and chemistry...
  30. ncbi request reprint Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter
    Mitchell Quinlivan
    Department of Pharmacology, University of Sydney, NSW 2006, Australia
    Nucl Med Biol 30:741-6. 2003
    ..In view of these results [(123)I]1 and [(123)I]2 do not appear to be suitable radioligands for in vivo studies of the SERT...
  31. ncbi request reprint Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand
    Michelle L James
    Department of Pharmacology, University of Sydney, NSW 2006, Australia
    Bioorg Med Chem 13:6188-94. 2005
    ..Furthermore, [11C]1 represents the first ligand of its pharmacological class to be labelled for PET studies and therefore has the potential to generate new information on the pathological role of the PBR in vivo...
  32. doi request reprint Cubyl amides: novel P2X7 receptor antagonists
    Hendra Gunosewoyo
    School of Chemistry, University of Sydney, NSW 2006, Australia
    Bioorg Med Chem Lett 18:3720-3. 2008
    ..All synthesised compounds possessed P2X7R antagonistic properties when tested on rat spinal cord microglia cells. Extensive screening for binding to other neuroreceptor subtypes demonstrated their P2X7 selectivity...
  33. doi request reprint P2X purinergic receptor ligands: recently patented compounds
    Hendra Gunosewoyo
    University of Sydney, School of Chemistry, NSW 2006, Australia
    Expert Opin Ther Pat 20:625-46. 2010
    ..Their wide expression in the CNS, recent advances in the biochemical and pharmacological properties as well as increasing numbers of patents published in this research domain demand a review in this field...
  34. ncbi request reprint Small animal SPECT and its place in the matrix of molecular imaging technologies
    Steven R Meikle
    School of Medical Radiation Sciences, Faculty of Health Sciences, University of Sydney, PO Box 170, Lidcombe, NSW 1825, Sydney, Australia
    Phys Med Biol 50:R45-61. 2005
    ....
  35. ncbi request reprint Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist
    Cyrille Thominiaux
    Service Hospitalier Frederic Joliot, Departement de Recherche Medicale, CEA DSV, 4 Place du General Leclerc, F 91401 Orsay, France
    Appl Radiat Isot 64:348-54. 2006
    ..8 to 1.2 Ci/micromol (29.6-44.4 GBq/micromol) at the end of radiosynthesis. No attempts were made to further optimise these reactions, as sufficient material was obtained to allow for preliminary pharmacological characterisation...
  36. ncbi request reprint Acetylenic pyridines for use in PET imaging of nicotinic receptors
    Alan P Kozikowski
    Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, USA
    ChemMedChem 2:54-7. 2007
  37. ncbi request reprint Development of radioligands for in vivo imaging of GABA(A)-benzodiazepine receptors
    Andrew Katsifis
    Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology Organisation, Private Mail Bag 1, Menai NSW 2234, Sydney, Australia
    Mini Rev Med Chem 4:909-21. 2004
    ....
  38. ncbi request reprint Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer
    Gaelle Roger
    Departement de Recherche Medicale, CEA DSV, 4 Place du General Leclerc, F 91401 Orsay, France
    Bioorg Med Chem 11:5401-8. 2003
    ..In view of these results, and especially considering the low brain penetration of the radiotracer, [(11)C]-1 does not have the required properties for imaging NMDA receptors using positron emission tomography...
  39. ncbi request reprint Imaging sigma receptors: applications in drug development
    Thomas Lee Collier
    Siemens Biomarker Solutions, 406 Industrial Drive, North Wales, PA 19454, USA
    Curr Pharm Des 13:51-72. 2007
    ..This review provides an overview of the current knowledge of these sites with a focus on specific areas where in vivo sigma receptor imaging is currently being investigated...
  40. ncbi request reprint Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors
    Andrew Katsifis
    Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology Organisation Menai NSW 2234, Sydney, Australia
    Nucl Med Biol 30:191-8. 2003
    ..S)-8-[(123)I]Iodobretazenil potently and selectively labels BZR in vivo and deserves further investigation as a possible SPECT radiotracer...
  41. ncbi request reprint Dopamine D1 receptor imaging in the rodent and primate brain using the isoquinoline +-[11C]A-69024 and positron emission tomography
    Laurent Besret
    CNRS, URA 2210, 4 Place du General Leclerc, F 91406 Orsay, France
    J Pharm Sci 97:2811-9. 2008
    ..Thus, (+)-[(11)C]A-69024 appears to be a specific and enantioselective radioligand to visualize and quantify brain dopamine D1 receptors in vivo using positron emission tomography...
  42. ncbi request reprint Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter
    Nicolas Giboureau
    INSERM, U619, 37000 Tours, France
    Synapse 61:962-70. 2007
    ..The in vivo PET study of [(18)F]2 performed in baboon also revealed rapid defluorination as the main problem. Therefore [(18)F]1 and [(18)F]2 appear to be unsuitable for in vivo imaging of the VAChT using PET...
  43. ncbi request reprint Influence of trishomocubanes on sigma receptor binding of N-(1-benzyl-piperidin-4-yl)-4-[123I]iodobenzamide in vivo in the rat brain
    Xiang Liu
    Department of Pharmacology The University of Sydney, NSW 2006 Australia
    Med Chem 1:31-8. 2005
    ..This demonstrates for the first time the ability of functionalised trishomocubanes to interact with sigma receptors in vivo...
  44. ncbi request reprint (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter
    Patrick Emond
    INSERM U619, 37000 Tours, France
    Nucl Med Biol 34:967-71. 2007
    ..These results made [125I]-( R,R)-5-AOIBV inferior to [125I]-IBVM for the VAChT exploration in vivo...
  45. ncbi request reprint Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands
    Thaer Assaad
    Universite Francois Rabelais de Tours, 37200 Tours, France
    Bioorg Med Chem Lett 16:2654-7. 2006
    ..These compounds will be soon radiolabeled with [(125)I] for further biological evaluation using single photon emission computed tomography (SPECT)...
  46. ncbi request reprint Positron emission tomography imaging of neuroinflammation
    Annachiara Cagnin
    Department of Neuroscience, University of Padova, Via Giustiniani 5, 35128, Padova, Italy
    Neurotherapeutics 4:443-52. 2007
    ....
  47. ncbi request reprint The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals
    Peter Roselt
    Centre for Positron Emission Tomography, Peter MacCallum Cancer Centre East Melbourne, Australia
    Eur J Drug Metab Pharmacokinet 29:1-6. 2004
    ..Consequently PET imaging of rodents is emerging as a cost effective means of screening new pharmaceuticals and decreasing the time required for new drug development...
  48. ncbi request reprint Molecular probes for P2X7 receptor studies
    Hendra Gunosewoyo
    School of Chemistry, University of Sydney, NSW 2006 Australia
    Curr Med Chem 14:1505-23. 2007
    ..This article will review P2X7R ligands discovered to date, together with their biological activity and therapeutic potential...
  49. ncbi request reprint 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation
    Herve Boutin
    CEA, Institut d Imagerie Biomédicale, Service Hospitalier Frederic Joliot, Laboratoire d Imagerie Moleculaire Experimentale, Orsay, France
    J Nucl Med 48:573-81. 2007
    ..Here we investigated a new PBR ligand suitable for PET to monitor neuroinflammatory processes as an indirect hallmark of neurodegeneration...
  50. ncbi request reprint Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands
    Johnny Vercouillie
    Universite Francois Rabelais de Tours, INSERM U619, Laboratoire de Biophysique Medicale et Pharmaceutique, 31 Avenue Monge, 37200 Tours, France
    Bioorg Med Chem Lett 16:1297-300. 2006
    ..Three of these exhibited good to high in vitro affinity (0.5 nM < K(i) < 11 nM) and selectivity for the SERT over the other monoamine transporters...